9099 related articles for article (PubMed ID: 17668534)
41. Management of metastatic melanoma 2005.
O'Day S; Boasberg P
Surg Oncol Clin N Am; 2006 Apr; 15(2):419-37. PubMed ID: 16632224
[TBL] [Abstract][Full Text] [Related]
42. Isolated limb perfusion for melanoma.
Kroon BB; Noorda EM; Vrouenraets BC; van Slooten GW; Nieweg OE
Surg Oncol Clin N Am; 2008 Oct; 17(4):785-94, viii-ix. PubMed ID: 18722918
[TBL] [Abstract][Full Text] [Related]
43. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.
Koon HB; Atkins MB
Expert Rev Anticancer Ther; 2007 Jan; 7(1):79-88. PubMed ID: 17187522
[TBL] [Abstract][Full Text] [Related]
44. Cytokines in dermatology.
Holman DM; Kalaaji AN
J Drugs Dermatol; 2006 Jun; 5(6):520-4. PubMed ID: 16774103
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
46. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Egberts F; Kahler KC; Livingstone E; Hauschild A
Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
[TBL] [Abstract][Full Text] [Related]
47. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
48. Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome.
Westermann J; Hecker AC; Flörcken A; Dörken B; Pezzutto A
J Immunother; 2009; 32(6):667-75. PubMed ID: 19483643
[TBL] [Abstract][Full Text] [Related]
49. Can surgeons improve survival in stage IV melanoma?
Mosca PJ; Teicher E; Nair SP; Pockaj BA
J Surg Oncol; 2008 Apr; 97(5):462-8. PubMed ID: 18270974
[TBL] [Abstract][Full Text] [Related]
50. [Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma?].
Kreutzer K; Bonnekoh B; Franke I; Ulrich J; Gollnick H
J Dtsch Dermatol Ges; 2004 Aug; 2(8):689-94. PubMed ID: 16279234
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677
[TBL] [Abstract][Full Text] [Related]
52. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma.
Finocchiaro LM; Glikin GC
Gene Ther; 2008 Feb; 15(4):267-76. PubMed ID: 18033308
[TBL] [Abstract][Full Text] [Related]
53. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
[TBL] [Abstract][Full Text] [Related]
54. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients.
Page AV; Liles WC
Curr Opin Organ Transplant; 2008 Dec; 13(6):575-80. PubMed ID: 19060545
[TBL] [Abstract][Full Text] [Related]
55. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
56. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
Tarhini AA; Millward M; Mainwaring P; Kefford R; Logan T; Pavlick A; Kathman SJ; Laubscher KH; Dar MM; Kirkwood JM
Cancer; 2009 Feb; 115(4):859-68. PubMed ID: 19140204
[TBL] [Abstract][Full Text] [Related]
57. Melanoma and immunotherapy.
Eggermont AM; Schadendorf D
Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
[TBL] [Abstract][Full Text] [Related]
58. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.
Martín-Algarra S; Espinosa E; Rubió J; López López JJ; Manzano JL; Carrión LA; Plazaola A; Tanovic A; Paz-Ares L
Eur J Cancer; 2009 Mar; 45(5):732-5. PubMed ID: 19186051
[TBL] [Abstract][Full Text] [Related]
60. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
